Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Recent advances in drug discovery against Mycobacterium tuberculosis: Metal-based complexes

Full text
Author(s):
Scarim, Caue Benito [1] ; de Farias, Renan Lira [2] ; de Godoy Netto, Adelino Vieira [2] ; Chin, Chung Man [1, 3] ; dos Santos, Jean Leandro [2, 1] ; Pavan, Fernando Rogerio [1]
Total Authors: 6
Affiliation:
[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, BR-14800903 Araraquara, SP - Brazil
[2] Sao Paulo State Univ UNESP, Inst Chem, BR-14800900 Araraquara, SP - Brazil
[3] Union Coll Great Lakes UNILAGO, Sch Med, BR-15030070 Sao Jose Do Rio Preto, SP - Brazil
Total Affiliations: 3
Document type: Review article
Source: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY; v. 214, MAR 15 2021.
Web of Science Citations: 0
Abstract

Metal-based drugs are privileged motifs that act as primary pharmacophores in bioactive compounds for various diseases, including tuberculosis (TB). This potentially life-threatening and extremely contagious infectious disease is caused by Mycobacterium tuberculosis (Mtb). In 2018, TB infected about 10 million people and caused 1.2 million deaths worldwide. A large number of ligands are promising scaffolds in drug design, including heterocyclic, phosphines, schiff bases, thio and semicarbazones, aliphatic amines, cyclopalladated, cyanometallates and miscellaneous. Moreover, several metal-based complexes have been studied for the treatment of numerous illnesses, including infectious diseases. To contribute to drug design, we identified the metal-based organometallic complexes against Mtb. Thus, in this review article, we analysed the recent contributions of metal-based scaffolds for design of new anti-Mtb drugs in the last decade (2011-2020). Besides, metal-based approaches will be presented in order to find out new antitubercular agents. (C) 2021 Elsevier Masson SAS. All rights reserved. (AU)

FAPESP's process: 16/10847-9 - Hydroxymethylnitrofurazone (NFOH): activity study in chronic phase of Chagas' Disease in an animal model and synthesis of soluble derivatives
Grantee:Cauê Benito Scarim
Support Opportunities: Scholarships in Brazil - Doctorate